Gengos Andrew

CFO Gengos Andrew purchased 10,000 shares at $3.93 (2 separate transactions totaling $39,283.00) at TERN, growing holdings 66.7%

Andrew Gengos, CFO of Terns Pharmaceuticals, executed 2 separate purchases totaling 10,000 shares for $39,283.00 at a blended average price of $3.93 on 2025-06-27, raising his post-transaction holdings to 25,000 shares from 15,000 shares (a +66.7% increase). The purchase price of $3.93 is modestly above the current price of $3.73 but well below the 52-week high of $11.23, reflecting a stock trading -66.8% from its peak. Most materially, Terns Pharmaceuticals reported a net income of $-23,908,000.00 and annual revenue growth of -100.0%, indicating the company is unprofitable and has contracted significantly. The insider's recent trading pattern at TERN shows 3 prior buys within the past two weeks (2025-06-13 and 2025-06-16), with outcomes not yet measurable at either the 30-day or 90-day horizon, leaving open questions about the basis for this accumulation amid deteriorating fundamentals.

CFO Gengos Andrew buys 15,000 shares across 3 transactions for $57,082.50 at blended average $3.81

Gengos Andrew, CFO of Terns Pharmaceuticals, purchased 15,000 shares (15.0K shares) across 3 separate transactions on June 13-16, 2025, at prices of $3.75, $3.72, and $3.95, totaling $57,082.50. The timing coincides with stock movement—the 30-day price change is +39.2%—and his post-transaction holdings now stand at 15,000 shares versus zero prior. The company faces significant headwinds: net income is $-23.9M and annual revenue growth is -100.0%, indicating the firm is unprofitable and has no top-line revenues to report. The 52-week range of $2.00–$11.23 shows the stock is currently -64.3% from its high, creating a substantially different risk-reward context than when earlier buyers entered. This purchase represents the CFO's first material position stake in the company and occurs in a period of compressed profitability and negative revenue trajectory, warranting review of the business rationale and any concurrent disclosure of strategic initiatives.